Exforge and Metastases to bone - a phase IV clinical study of FDA data

Summary:

Metastases to bone is reported as a side effect among people who take Exforge (amlodipine besylate; valsartan), especially for people who are male, 60+ old, also take Hyzaar, and have Diabetes.

The phase IV clinical study analyzes which people have Metastases to bone when taking Exforge. It is created by eHealthMe based on reports of 12,942 people who have side effects when taking Exforge from the FDA, and is updated regularly.

What is Exforge?

Exforge has active ingredients of amlodipine besylate; valsartan. It is often used in high blood pressure. eHealthMe is studying from 13,350 Exforge users. Check the latest studies of Exforge.

What is Metastases to bone?

Metastases to bone (cancer spreads to bone) is found to be associated with 1,127 drugs and 902 conditions by eHealthMe. Check the latest studies of Metastases to bone.

On Jul, 21, 2026

12,942 people reported to have side effects when taking Exforge.
Among them, 13 people (0.1%) have Metastases to bone.

Among these 13 people:

What is the gender of people who have Metastases to bone when taking Exforge? *

female: 38.46 %
male: 61.54 %

What is the age of people who have Metastases to bone when taking Exforge? *

What are other drugs people take besides Exforge? *

What are other side effects people have besides Metastases to bone? *

Metastases To Lung (cancer spreads to lung): 4 people, 30.77%
Metastases To Central Nervous System (cancer spreads to central nervous system): 2 people, 15.38%
Prostate Cancer: 2 people, 15.38%
Pain: 2 people, 15.38%
Wound: 1 person, 7.69%
Depression: 1 person, 7.69%
High Blood Cholesterol: 1 person, 7.69%
Hiatal Hernia (hernia resulting from the protrusion of part of the stomach through the diaphragm): 1 person, 7.69%
Hernia (hernia happens when part of an internal organ or tissue bulges through a weak area of muscle): 1 person, 7.69%
Hepatic Mass: 1 person, 7.69%

What are the existing conditions these people have? *

Diabetes: 3 people, 23.08%
Renal Cell Carcinoma (a kidney cancer): 1 person, 7.69%
Psoriasis (immune-mediated disease that affects the skin): 1 person, 7.69%
Peripheral Arterial Occlusive Disease (reproducible ischemic muscle pain): 1 person, 7.69%
Neoplasm Malignant (cancer tumour): 1 person, 7.69%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 7.69%
Endometrial Cancer: 1 person, 7.69%
Depression: 1 person, 7.69%
Barrett's Oesophagus (barrett's oesophagus is a disorder in which the lining of the oesophagus (the tube that carries food from the throat to the stomach) is damaged by stomach acid and changed to a lining similar to that of the stomach): 1 person, 7.69%
Arrhythmias (irregular heartbeat): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Exforge and have Metastases to bone?

- Check whether Metastases to bone is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Exforge:

Exforge (13,350 reports)

Metastases to bone treatments and more:

Metastases to bone (51,059 reports)

How severe was Metastases to bone and when was it recovered:

Metastases to bone in Exforge

Expand to all the drugs that have ingredients of amlodipine besylate; valsartan:

Metastases to bone and drugs with ingredients of amlodipine besylate; valsartan

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Exforge:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Metastases to bone:

Metastases to bone (1,127 drugs)

Browse all the conditions that are associated with Metastases to bone:

Metastases to bone (902 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on amlodipine besylate; valsartan (the active ingredients of Exforge) and Exforge (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.